Article
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jun 2010
Sequist Lecia V, Besse Benjamin, Lynch Thomas J, Miller Vincent A, Wong Kwok K, Gitlitz Barbara, Eaton Keith, Zacharchuk Charles, Freyman Amy, Powell Christine, Ananthakrishnan Revathi, Quinn Susan, Soria Jean-Charles
Abstract excerpt
PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations. Resistance emerges after 9 to 12 months, primarily mediated by the T790M resistance mutation. We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M. PATIENTS AND METHODS: Patients with...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Female
- Humans
- International Agencies